Avalon GloboCare Corp. (NASDAQ:ALBT) Short Interest Up 41.2% in December

Avalon GloboCare Corp. (NASDAQ:ALBT) was the target of a large increase in short interest in December. As of December 15th, there was short interest totaling 80,987 shares, an increase of 41.2% from the November 30th total of 57,363 shares. Currently, 2.1% of the shares of the stock are sold short. Based on an average daily trading volume, of 193,362 shares, the days-to-cover ratio is currently 0.4 days. Based on an average daily trading volume, of 193,362 shares, the days-to-cover ratio is currently 0.4 days. Currently, 2.1% of the shares of the stock are sold short.

Avalon GloboCare Stock Up 5.6%

Shares of NASDAQ ALBT opened at $1.33 on Monday. Avalon GloboCare has a 12-month low of $0.88 and a 12-month high of $11.66. The firm’s 50-day simple moving average is $1.65 and its 200 day simple moving average is $2.18. The company has a market cap of $5.65 million, a price-to-earnings ratio of -0.38 and a beta of -0.11.

Avalon GloboCare (NASDAQ:ALBT) last announced its earnings results on Friday, November 14th. The company reported ($0.06) earnings per share for the quarter. The business had revenue of $0.35 million for the quarter.

Analysts Set New Price Targets

Several research analysts have issued reports on ALBT shares. Weiss Ratings reiterated a “sell (e+)” rating on shares of Avalon GloboCare in a research note on Wednesday, October 8th. Wall Street Zen lowered shares of Avalon GloboCare to a “strong sell” rating in a report on Saturday, September 13th. One equities research analyst has rated the stock with a Sell rating, Based on data from MarketBeat, Avalon GloboCare has an average rating of “Sell”.

Avalon GloboCare Company Profile

Avalon GloboCare is a clinical-stage biopharmaceutical company specializing in the research, development and commercialization of next-generation cell-based therapies and exosome-based diagnostics. The company’s pipeline focuses on allogeneic chimeric antigen receptor T-cell (CAR-T) and CAR-natural killer (CAR-NK) programs targeting hematological malignancies and solid tumors, alongside proprietary exosome platforms for noninvasive cancer detection.

Through its R&D facilities in both the United States and China, Avalon GloboCare integrates cell engineering, genetic modification and biomarker discovery to advance therapeutic and diagnostic candidates from preclinical research into human studies.